The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The final analysis of a phase I/II study of nivolumab, ipilimumab combined with nintedanib in advanced non-small cell lung cancer.
 
Sonam Puri
Honoraria - Aptitude Health (Inst); IntegrityCE
Consulting or Advisory Role - AstraZeneca (Inst); G1 Therapeutics (Inst); Jazz Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Dava Oncology
 
Tawee Tanvetyanon
No Relationships to Disclose
 
Ben C. Creelan
Honoraria - Achilles Therapeutics; AstraZeneca; ER Squibb & Sons, LLC; Instil BIO; Roche
Speakers' Bureau - AstraZeneca; Novartis
Research Funding - Cancer Research Institute (Inst); Clinigen Group; E. R. Squibb & Sons, LLC (Inst)
Patents, Royalties, Other Intellectual Property - Patent WO2020263919A1 pending; Patent WO2021163695A2 pending
Travel, Accommodations, Expenses - AstraZeneca
 
Michael Rahman Shafique
Consulting or Advisory Role - GlaxoSmithKline; Jazz Pharmaceuticals
Research Funding - Amphivena (Inst); Daiichi Sankyo/Lilly; Merck Serono (Inst); Nektar (Inst); Pfizer (Inst); Vaccinex (Inst)
Travel, Accommodations, Expenses - Janssen Research & Development; Nektar; Vaccinex
 
Andreas Nicholas Saltos
Honoraria - MJH Life Sciences (I)
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Lilly; Zymeworks
Research Funding - AstraZeneca (Inst); BioAtla (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Genmab (Inst); Lilly (Inst); Memgen (Inst); Mersana (Inst); Novartis (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Prime Oncology
 
Alberto Chiappori
Stock and Other Ownership Interests - Merck
Consulting or Advisory Role - Abbvie; Ailleron; G1 Therapeutics; Jazz Pharmaceuticals; Merus; Sanofi/Regeneron
Speakers' Bureau - Amgen; Blueprint Medicines; Genentech; Takeda
Research Funding - AstraZeneca; Bristol-Myers Squibb; Jazz Pharmaceuticals
Travel, Accommodations, Expenses - Amgen; Takeda
 
Eric B. Haura
Consulting or Advisory Role - Amgen; Ellipses Pharma; Janssen; Janssen; Janssen Research & Development; Kanaph Therapeutics; ORI Capital; ORI Capital; ORI Capital; Revolution Medicines
Research Funding - AstraZeneca (Inst); Genentech (Inst); Janssen (Inst); Novartis (Inst); Revolution Medicines (Inst); Spectrum Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Protein-Protein Interactions as Biomarkers Patent
 
Ram Thapa
No Relationships to Disclose
 
Dung-Tsa Chen
No Relationships to Disclose
 
Theresa A. Boyle
Stock and Other Ownership Interests - Ionis Pharmaceuticals
Research Funding - Bristol Meyers Squibbs
 
Scott Joseph Antonia
Consulting or Advisory Role - Achilles Therapeutics; Amgen; Celsius Therapeutics; EMD Serono; G1 Therapeutics; GlaxoSmithKline
Research Funding - Cellular Biomedicine Group (Inst)
Travel, Accommodations, Expenses - Amgen
 
Jhanelle Elaine Gray
Honoraria - Jazz Pharmaceuticals; Merck; OncoCyte
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca/MedImmune; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Bristol Myers Squibb; EMD Serono; Janssen Scientific Affairs; Jazz Pharmaceuticals; Lilly; Loxo; Merck Sharp & Dohme; National Comprehensive Cancer Network; Novartis; Sanofi
Research Funding - Array BioPharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); ECOG-ACRIN (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); SWOG (Inst)
Travel, Accommodations, Expenses - Novartis; OncoCyte